At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 61 enrolled

Drug / intervention

r-HuEPOdrug

Likely dose

r-HuEPO 10000 IUfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02767765

NCT02767765Phase 3Completed

Compare CT.gov

Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy

Hoffmann-La Roche·interventional·Posted May 10, 2016·Updated Apr 4, 2017

In Brief

A Phase 3 clinical trial evaluating r-HuEPO for Anemia. Completed, enrolled 61 participants across 7 sites.

Detailed Summary

This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAnemia

CountriesItaly

Collaborators--

Timeline

Phase 3CompletedFinished

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJun 2003

Primary CompletionOct 2006

First PostedMay 2016

TodayJul 2026

First PostedMay 10, 2016

Enrollment StartJun 1, 2003

Primary CompletionOct 1, 2006

TodayJul 2, 2026

Enrollment to primary: 3.3 yearsPosted 10.1 years ago

Interventions

r-HuEPOdrug

All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.